亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

目的 通过动态观察亚低温对急性重型颅脑损伤患者血清S-100B蛋白浓度的影响,探讨亚低温在急性重型颅脑损伤治疗中的作用.方法 将120例急性重型颅脑损伤患者随机数字表法分为亚低温组和常规组.亚低温组在常规治疗的基础上,予亚低温治疗,直肠温度维持在33～35℃,持续3～5 d.所有患者于入院6 h内,入院后第2,3,4,5,6天动态检测血清S-100B蛋白浓度.3个月后对患者进行GOS评估.结果 亚低温组和常规组血清S-100B蛋白浓度明显高于正常对照组(P<0.05);亚低温组血清S-100B蛋白浓度明显低于常规组(P<0.05);亚低温能够改善急性重型颅脑损伤患者的预后.结论 早期应用亚低温能显著降低急性重型颅脑损伤患者血清S-100B蛋白浓度,保护神经功能,改善预后,其脑保护作用可能与亚低温能减轻S-100B蛋白介导的损伤性脑细胞炎症反应有关.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

亚低温对急性重型颅脑损伤患者血清S-100 B蛋白的影响

Objective To dynamically observe the effect of mild hypothermia on concentration of plasma S-100B protein in patients with acute severe brain injuries so as to further explore its role in treat-ment of acute severe brain injury. Methods A total of 120 patients with acute severe brain injuries were randomly divided into mild hypothermia group and general group. The patients in mild hypothermia group were treated with mild hypothermia besides conventional therapy, with maintenance of rectal tem-perature at 33℃-35℃ for 3-5 days. Serial concentration of S-IOOB protein in serum was measured in all patients from 6 hours to 6 days after hospitalization. GOS evaluation was done three months after treat-ment. Results The concentration of S-100B protein in serum of mild hypothermia group and general group was significantly higher than of normal group (P <0.05), with significant lower level in mild hypo-thermia group than general group(P <0.05). Mild hypothermia could improve prognosis of patients with acute severe brain injury. Conclusions Early use of mild hypothermia can decrease concentration of S-100B protein in serum, protect neurofunction and improve prognosis, as may be related to its function in alleviating damnification brain cell inflammation reaction mediated by S-100B protein.     

高压氧综合治疗急性脑梗死的疗效及最佳治疗时间窗的研究

目的 比较高压氧(hyperbaric oxygen,HBO)治疗与常规疗法治疗急性脑梗死(acute cerebral infarction,ACI)的疗效及探讨HBO治疗的最佳治疗时间窗.方法 将2006年6月至2010年12月入住我院的ACI患者196例经知情同意后分为HBO组(98例)和对照组(98例),HBO组再按HBO 治疗时间分为＜6h、6～48 h、＞48 h3个亚组,在常规治疗的基础上加用HBO,HBO治疗采用多人氧舱,在舱内停留120 min,压力0.25 MPa(2.5 ATA),戴面罩吸入纯氧60 min(30 min 2次,中间间歇10min吸舱内空气),加、减压各25 min,1次/d,10d为1个疗程,疗程间隔3～5d,共3个疗程.对照组按照病程亦分为＜6h、6～48 h、＞48 h3个亚组.对所有患者分别于治疗前及疗程结束后进行美国国立卫生研究院卒中量表(NIHSS)评分和Barthel指数(BI)评分,并与常规治疗的ACI患者(对照组)进行比较.结果 治疗后HBO各亚组的总有效率(97.3％、90.0％、80.7％)显著高于常规治疗各亚组(85.7％、77.1％、57.1％)(均为P＜0.01);HBO组中＜6h亚组的有效率明显高于6～48 h和＞48 h亚组(P＜0.05),各亚组NIHSS评分明显低于常规治疗组,BI评分明显高于常规治疗组各亚组(均为P＜0.01);HBO组中＜6h亚组明显优于6～48 h和＞48 h亚组(P＜0.05).结论 HBO治疗ACI的疗效显著,并且在发病6h内开始治疗为最佳.     

高压氧早期综合治疗急性脑梗死的临床疗效观察

目的 探讨高压氧早期治疗急性脑梗死的临床疗效.方法 132例急性脑梗死患者,按照高压氧治疗时期分为早期治疗组(发病后7 d内)及晚期治疗组(发病14 d后).高压氧治疗30次后采用改良的爱丁堡-斯堪的纳维亚量表进行神经功能缺损评分(NFD),用改良的Barthel指数(MBI)进行患者的日常生活活动能力评分(ADL).结果 2组患者治疗后的NFD、MBI评分比较差异有统计学意义(P<0.05).结论 高压氧早期治疗对急性脑梗死患者的神经功能恢复、日常生活活动能力均有良好的促进作用,对急性脑梗死的患者应尽早进行高压氧治疗.     

高压氧治疗急性脑梗塞的临床分析

目的观察高压氧（HBO）治疗急性脑梗塞患者的疗效并进行临床分析。方法回顾性研究我院2000年1月至2005年2月急性脑梗塞住院病例共466例。其中高压氧＋药物治疗组（HBO组）303例；单纯药物治疗组（对照组）163例。根据“欧洲卒中量表”（ESS）对HBO组于HBO治疗前、后，对照组于入、出院时分别进行评分并观察疗效。结果HBO组治疗重、中度脑梗塞患者与对照组相比，ESS评分分别有非常显著性差异（P〈0．01）、显著性差异（P〈0．05）；HBO组治疗椎一基底动脉系统脑梗塞与对照组相比，差异有显著性意义（P〈0．05）。HBO治疗次数超过10次组与对照组相比，ESS评分有显著性差异（P〈0．05）。结论重、中度急性脑梗塞和椎一基底动脉系统脑梗塞HBO综合治疗好于单纯药物治疗。HBO治疗次数超过10次组的疗效优于HBO治疗次数不足10次组。     

高压氧综合治疗急性脑梗死一年期内疗效分析

目的 探讨脑梗死急性期行高压氧治疗对患者1年内神经功能恢复的影响.方法 急性脑梗死患者192例分为高压氧组和非高压氧组,分别于治疗前、治疗20 d、3个月、6个月、12个月时进行神经功能缺损评分对比.根据治疗前神经功能缺损评分,每组患者冉被分为轻、中、重3个亚组进行分析.结果 (1)神经功能缺损轻型组:治疗后各评分时间高压氧组均较非高压氧组有显著改善(P<0.01或P<0.05).(2)神经功能缺损中型组:高压氧20 d组、12个月组较同期非高压氧组有明显改善,差异有统计学意义(P<0.05).(3)神经功能缺损重型组:高压氧6个月组、12个月组较同期非高压氧组有明显改善,差异有统计学意义(P<0.05).(4)高压氧组1年死亡率较非高压氧组有明显降低,差异有统计学意义(P<0.01).高压氧组1年复发率较非高压氧组有明显降低,差异有统计学意义(P<0.05).结论 脑梗死患者急性期行高压氧治疗不仪可以改善患者急性期神经缺损,而且在1年内仍可使患者受益,改善神经功能,降低死亡率及复发率.     

高压氧对急性脑梗死患者血浆D-二聚体含量的影响

目的　探讨高压氧 (HBO)治疗脑梗死患者对血浆 D-二聚体 (D-dimer)含量的影响。方法　对 3 6例正常人对照组、1 69例 HBO组与 87例同期常规治疗组的脑梗死急性期血浆 D-dim er含量变化进行观察。结果　 HBO组和常规治疗组患者第 1天、第 1 0天的血浆 D-dim er水平高于正常对照组 (P<0 .0 5)。 HBO组患者第 1 0天的水平低于同期常规治疗组 (P<0 .0 5)。结论　 HBO治疗使急性脑梗死患者血浆 D-dim er含量降低     

血浆S-100B蛋白测定在外伤性颅内血肿诊疗中的临床意义

目的 探讨血浆S-100B蛋白在不同类型外伤性颅内血肿的诊断、分型、指导治疗中的临床价值.方法 颅内血肿116例,根据头颅CT分为硬膜外血肿(52例)、硬膜下血肿(32例)、脑内血肿(32例)三组,伤后早期(6小时内)抽取血浆测定S-100B蛋白含量,伤后每24小时送检1次,动态测定(3～7天).三组两两比较.结果 脑...     

大鼠全脑照射后早期血清S-100B变化特征

目的 观察大鼠全脑不同剂量照射后1月内不同时间点血清中S-100B的变化,以探讨S-100B在早期放射性脑损伤中的变化特征。方法 对大鼠予4 MeV电子线分别单次全脑照射2、10和30 Gy制备大鼠早期放射性脑损伤模型。采用酶联免疫吸附试验(ELISA)检测照射后1 h、6 h、12 h、24 h、3 d、1周、1个月血清中S-100B的浓度。结果 大鼠血清S-100B浓度在照射后6h升高最明显,照射后12h浓度下降,照后24h再升高(除外2 Gy组为在照射后3d再升高), 随后下降直到最后观察时间点。结论 大鼠全脑照射后血清S-100B水平发生了变化,不同剂量组血清S-100B浓度有显著性差异,剂量越高,浓度越高。结果提示S-100B可能会成为检测早期放射性脑损伤的重要血清指标。     

高压氧对实验性大鼠血栓栓塞性脑梗死出血性转换的影响

目的研究高压氧对急性脑梗死并发脑出血的影响。方法用自体血栓法制作大鼠大脑中动脉栓塞（MCA9）模型，用SD大鼠36只，随机分成3组：手术对照组、常氧高氮组、高压氧（HBO）治疗组。观察HBO对脑梗死出血转换发生率的影响。结果脑梗死转换出血的自然发生率为33．3％，常氧高氮组的发生率为25．0％，高压氧组为33．3％，高压氧组与手术对照组及常氧高氮组相比出血率无明显提高（P〉0．05）。结论高压氧对大鼠血栓性脑梗死出血性转换的发生率无明显的影响。     

高压氧干预下急性脑梗死患者细胞黏附分子变化及对预后的影响

目的 对急性脑梗死(acute cerebral infarction,ACI)患者CD11b、CD11c和CD54作动态观察,找出其变化规律及高压氧(hyperbaric oxygen,HBO)对该规律的影响,并进一步阐明HBO对ACI患者脑血管的保护作用;同时对ACI患者治疗前CD11b、CD11c和CD54与近、远期神经功能恢复程度相关性进行探讨.方法 64例ACI患者分2组:HBO组31例,常规治疗联合HBO治疗;治疗对照组33例,仅行常规治疗.2组分别在治疗前(发病≤72 h)及治疗第7、10、12、20天晨抽取外周静脉血测定CD11b、CD11c和CD54,并在相同治疗时间进行神经功能缺损程度评分(neural functional damage scores,NDS).另外选取正常对照组25人,仅抽取周围静脉血测定CD11b、CD11c和CD54.结果 HBO组和治疗对照组治疗前CD11b、CD11c和CD54表达明显升高,达到高峰,2组各指标差异无统计学意义(P＞0.05),第7天均开始下降.HBO组CD11b、CD11c高峰持续时间为7d,治疗对照组持续10 d;HBO组CD54高峰持续时间为10 d,治疗对照组持续12d.经相关性和线性回归分析发现,发病第20天时NDS水平(近期疗效)和发病半年、1年时NDS的水平(远期疗效)分别为97.2％、96.7％及97.6％,可用CD11b和/或CD11c和/或CD54的上调水平以及其他相关因素解释.结论 HBO治疗后可缩短ACI患者CD11b、CD11c和CD54高峰持续时间.说明HBO可干预细胞黏附分子的变化过程,缩短其异常时限,减少它们的表达,对ACI患者有保护作用,并减少白细胞的黏附.同时治疗前CD11b、CD11c和CD54的表达可预测病情的轻重,影响近、远期疗效,为研究如何调控或抑制CD11b、CD11c和CD54的表达、减少对血管的损伤及早期制定更全面的治疗方案提供依据.     

依达拉奉联合高压氧治疗脑梗死83例疗效观察

目的 观察依达拉奉联合高压氧(HBO)治疗83例急性脑梗死患者的效果.方法 166例急性脑梗死患者分为依达拉奉治疗组(药物组)和依达拉奉联合HBO治疗组(HBO综合组),每组83例.药物组每天2次静脉滴注依达拉奉30 mg,HBO综合组除用依达拉奉治疗外,每天行HBO治疗1次,压力0.22 MPa,时间80 min,共治疗21 d,对2组患者住院3周后进行神经功能评分,以观察疗效,检测凝血酶原时间(PT)和纤维蛋白原(FIB)水平.结果 治疗第2周、第3周HBO综合组神经功能评分和疗效显著高于治疗前和药物组(P<0.05或0.01);HBO综合组PT的增高幅度大于药物组(P<0.05),血浆FIB水平则显著低于药物组(P<0.05或0.01).结论 依达拉奉联合HBO治疗的效果优于单纯用药,且HBO综合治疗可使PT增高和FIB水平显著降低.